A Phase 4 interventional study of PRP in Rectal Fistula, sponsored by University Hospital, Basel, Switzerland. Withdrawn at 1 site in Switzerland. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2016-02-10.
Sponsored by University Hospital, Basel, Switzerland · Phase 4, Interventional, and Treatment
Anal fistula is a very common disease with a high impact on life quality. The only commonly accepted treatment option is surgery. A wide range of operations and techniques have been developed all suffering from a relatively high recurrence rate.
The investigators propose the combination of the mucosal advancement flap with application of platelet-rich plasma (PRP) in the fistulectomy site. This study aims to test the hypothesis that by applying PRP the healing rate of complicated anal fistulas can be improved in comparison to a control group where the operation is performed without addition of PRP.
189 studies on the registry are indexed under Rectal Fistula; 42 are open to participants now.
Browse Rectal Fistula studies →University Hospital, Basel, Switzerland is the lead sponsor of 968 studies on the registry; 191 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The operation will be performed with application of platelet rich plasma
Biological: PRP
The operation will be performed without addition of platelet-rich plasma
Application of platelet-rich plasma during surgery
Healing rate
Time frame: 2 Years
Influence of risk factor smoking on healing rate
Time frame: 2 years
Influence of risk factor high BMI on healing rate
Time frame: 2 years
Influence of risk factor chronic renal failure on healing rate
Time frame: 2 years
Influence of sex on healing rate
Time frame: 2 years
This study is withdrawn, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Basel, Switzerland